Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate

Psychiatry Research

Volumn 210, Issue 3, 2013, Pages 761-768

  Bošković, Marija ^a   Grabnar, Iztok ^a   Terzič, Tea ^b   Kores Plesničar, Blanka ^b   Vovk, Tomaž ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Extrapyramidal symptoms; Haloperidol decanoate; Neurotransmitters; Oxidative stress; Psychopathology of schizophrenia

Indexed keywords

CATALASE; DOPAMINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HALOPERIDOL; HALOPERIDOL DECANOATE; MALONALDEHYDE; NITRATE; NITRITE; NORADRENALIN; SUPEROXIDE DISMUTASE; ANTIOXIDANT; GLUTATHIONE; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; AKATHISIA; ANTIOXIDANT ACTIVITY; ARTICLE; BARNES AKATHISIA SCALE; DOPAMINE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; NORADRENALIN BLOOD LEVEL; OXIDATIVE STRESS; PARANOID SCHIZOPHRENIA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; TARDIVE DYSKINESIA; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; EXTRAPYRAMIDAL SYNDROME; MENTAL DISEASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PSYCHOPATHOLOGY; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE;

EID: 84888287019     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.08.035     Document Type: Article

References (54)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. International Journal of Neuropsychopharmacology 2004, 7(1):S1-5.
2. Aebi H. Catalase in vitro. Methods in Enzymology 1984, 105:121-126.
3. Akanji A.O., Ohaeri J.U., Al-Shammri S.A., Fatania H.R. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clinical Biochemistry 2007, 40:1026-1031.
4. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., Savas H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Progress in Neuro-psychopharmacology & Biological Psychiatry 2002, 26:995-1005.
5. Altuntas I., Aksoy H., Coskun I., Caykoylu A., Akcay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clinical Chemistry and Laboratory Medicine 2000, 38:1277-1281.
6. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003, 62:195-204.
7. Boskovic M., Vovk T., Kores Plesnicar B., Grabnar I. Oxidative stress in schizophrenia. Current Neuropharmacology 2011, 9:301-312.
8. Boskovic M., Vovk T., Saje M., Goricar K., Dolzan V., Kores Plesnicar B., Grabnar I. Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia. Neurochemical Research 2013, 38:433-442.
9. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Research 1990, 31:1-14.
10. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. Journal of Neurochemistry 2010, 113:649-660.
11. Dakhale G., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
12. Devoto P., Flore G., Pani L., Gessa G.L. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Molecular Psychiatry 2001, 6:657-664.
13. Dietrich-Muszalska A., Malinowska J., Olas B., Glowacki R., Bald E., Wachowicz B., Rabe-Jablonska J. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochemical Research 2012, 37:1057-1062.
14. Dietrich-Muszalska A., Olas B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets 2009, 20:90-96.
15. Hermida-Ameijeiras A., Mendez-Alvarez E., Sanchez-Iglesias S., Sanmartin-Suarez C., Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochemistry International 2004, 45:103-116.
16. Holley F.O., Magliozzi J.R., Stanski D.R., Lombrozo L., Hollister L.E. Haloperidol kinetics after oral and intravenous doses. Clinical Pharmacology and Therapeutics 1983, 33:477-484.
17. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
18. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Ruther E., Emrich H.M., Schneider U., Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. Journal of Neuropsychiatry and Clinical Neurosciences 2005, 17:227-231.
19. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function 2002, 20:171-175.
20. Li X.F., Zheng Y.L., Xiu M.H., da Chen, Kosten C., Zhang, X.Y.T.R. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2011, 35:1064-1067.
21. Lieberman J.A., Koreen A.R. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophrenia Bulletin 1993, 19:371-429.
22. Lundberg J.O., Weitzberg E., Gladwin M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nature Reviews Drug Discovery 2008, 7:156-167.
23. Madrigal J.L., Kalinin S., Richardson J.C., Feinstein D.L. Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. Journal of Neurochemistry 2007, 103:2092-2101.
24. Madrigal J.L., Leza J.C., Polak P., Kalinin S., Feinstein D.L. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. Journal of Neuroscience 2009, 29:263-267.
25. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2001, 25:463-493.
26. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., Takanashi J., Matsuda T., Shimizu E., Ikehira H., Iyo M., Hashimoto K. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PloS One 2008, 3:e1944.
27. Murata T., Maruoka N., Omata N., Takashima Y., Igarashi K., Kasuya F., Fujibayashi Y., Wada Y. Effects of haloperidol and its pyridinium metabolite on plasma membrane permeability and fluidity in the rat brain. Progress in Neuro-psychopharmacology & Biological Psychiatry 2007, 31:848-857.
28. Nishioka N., Arnold S.E. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. American Journal of Geriatric Psychiatry 2004, 12:167-175.
29. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neuroscience Letters 2010, 479:317-320.
30. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 2004, 9(684-697):643.
31. Raffa M., Fendri C., Ben Othmen L., Slama H., Amri M., Kerkeni A., Mechri A. The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2012, 39:52-56.
32. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Progress in Neuro-psychopharmacology & Biological Psychiatry 2009, 33:1178-1183.
33. Reif A., Herterich S., Strobel A., Ehlis A.C., Saur D., Jacob C.P., Wienker T., Topner T., Fritzen S., Walter U., Schmitt A., Fallgatter A.J., Lesch K.P. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Molecular Psychiatry 2006, 11:286-300.
34. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. Journal of Neurochemistry 1998, 71:1002-1012.
35. Schraml E., Quan P., Stelzer I., Fuchs R., Skalicky M., Viidik A., Schauenstein K. Norepinephrine treatment and aging lead to systemic and intracellular oxidative stress in rats. Experimental Gerontology 2007, 42:1072-1078.
36. Smythies J. The adrenochrome hypothesis of schizophrenia revisited. Neurotoxicity Research 2002, 4:147-150.
37. Traver S., Salthun-Lassalle B., Marien M., Hirsch E.C., Colpaert F., Michel P.P. The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Molecular Pharmacology 2005, 67:1882-1891.
38. Troadec J.D., Marien M., Darios F., Hartmann A., Ruberg M., Colpaert F., Michel P.P. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. Journal of Neurochemistry 2001, 79:200-210.
39. Ustundag B., Atmaca M., Kirtas O., Selek S., Metin K., Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry and Clinical Neurosciences 2006, 60:458-464.
40. van Faassen E.E., Bahrami S., Feelisch M., Hogg N., Kelm M., Kim-Shapiro D.B., Kozlov A.V., Li H., Lundberg J.O., Mason R., Nohl H., Rassaf T., Samouilov A., Slama-Schwok A., Shiva S., Vanin A.F., Weitzberg E., Zweier J., Gladwin M.T. Nitrite as regulator of hypoxic signaling in mammalian physiology. Medicinal Research Reviews 2009, 29:683-741.
41. Virgos C., Martorell L., Valero J., Figuera L., Civeira F., Joven J., Labad A., Vilella E. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophrenia Research 2001, 49:65-71.
42. Webb A., Bond R., McLean P., Uppal R., Benjamin N., Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13683-13688.
43. Wu Z., Zhang X.Y., Wang H., Tang W., Xia Y., Zhang F., Liu J., Fu Y., Hu J., Chen Y., Liu L., Chen da C., Xiu M.H., Kosten T.R., He J. Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms. Progress in Neuro-psychopharmacology & Biological Psychiatry 2012, 36:34-38.
44. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. Journal of Neurochemistry 1998, 71:274-280.
45. Yamamoto K., Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry 2004, 28:913-922.
46. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxidants & Redox Signaling 2011, 15:2011-2035.
47. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research 1998, 32:1-8.
48. Young J., McKinney S.B., Ross B.M., Wahle K.W., Boyle S.P. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins, Leukotrienes and Essential Fatty Acids 2007, 76:73-85.
49. Zhang M., Zhao Z., He L., Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Science China Life sciences 2010, 53:112-124.
50. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81:291-300.
51. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., Kosten T.A., Kosten T.R. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. Journal of Clinical Psychiatry 2007, 68:754-760.
52. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophrenia Research 2003, 62:245-250.
53. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., Chen da C., Xiu M.H., Kosten T.A., Kosten T.R. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.
54. Zhang Z., Naughton D., Winyard P.G., Benjamin N., Blake D.R., Symons M.C. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochemical and Biophysical Research Communications 1998, 249:767-772.